Diabetes Vaccine | ASweetLife

Diabetes Vaccine: New Treatment Attacks Diabetes Before it Starts

Is the best way to beat type 1 diabetes to simply stop it before it starts? That’s a question being tackled in new clinical trial that proposes to prevent diabetes in those prone to developing it. “Often times, the best answer is the simple answer,” says Ezio Bonifacio, Ph.D., from the Center for Regenerative Therapies, in Dresden, who led a team of researchers to develop a vaccine to prevent type 1 diabetes. The vaccine has ended up being insulin itself.

Diamyd-Licensed Technology Cures Type 1 Diabetes in Mice

Researchers at UCLA have confirmed earlier findings that combinations of GABA and Antigen Based Therapy (ABT) works synergistically as a treatment in the NOD mouse model of type 1 diabetes. Diamyd Medical is the exclusive licensee for the commercialization of UCLA's GABA technology for metabolic diseases including in diabetes.

Lawrence Steinman’s ‘Reverse Vaccine’ Targets Immune Response in Type 1 Diabetes

Sometimes, when you’re stuck and spinning your wheels without making much forward progress, putting it in reverse can get you going. That’s what Dr. Lawrence Steinman and his colleagues are doing by attempting to cure type 1 diabetes with a unique and groundbreaking “reverse vaccine.”

Diamyd to Launch New Clinical Study of Diabetes Vaccine in Children

Diamyd Medical is planning to launch a new clinical study with its diabetes vaccine, Diamyd, during February 2013. The study, approved by the Swedish Medical Products Agency, combines the diabetes vaccine Diamyd with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Experimental Drug May Protect From Type 1 Diabetes

JDRF-funded researchers at Harvard School of Public Health have found that an experimental drug, called TUDCA, can dramatically reduce the occurrence of type 1 diabetes...

DiaPep277 Granted Orphan Drug Designation by FDA

The U.S. FDA has granted Orphan Drug designation for DiaPep277 for the treatment of type 1 diabetes (T1D) patients with residual beta cell function. The designation of Orphan Drug status offers 7 years marketing exclusivity from the time of approval....

Diapep277: Slowing the Progression of Type 1 Diabetes

Diapep277 was discovered in 1990 by Professor Irun Cohen and his team at the Weizmann Institute's Department of Immunology...

Positive Results for DiaPep277 Type 1 Diabetes Treatment in Phase 3 Study

Andromeda Biotech has announced positive initial results from a pivotal phase III clinical study of type 1 diabetes treatment, DiaPep227. The 24-month randomized, placebo-controlled study was designed to assess the safety and efficacy of DiaPep277, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with type 1 diabetes...

Diamyd Shifts Away from Diabetes To Cut Costs

Diamyd Medical announced it has shifted its focus from the development of the diabetes therapy Diamyd® to the the development of drug candidates for the treatment of chronic pain....

Diamyd Terminates US Phase III Study, DiaPrevent

Diamyd Medical has suspended dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd® following consultation with the US Food and Drug Administration (FDA). Termination follows a blinded review of the efficacy data collected to date in the study as well as the previously reported negative outcome...